Clinical Trial: NCT02445248
Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Novartis Pharmaceuticals |
| Information Provided By: | Novartis |
| Last Update Posted: | 2024-04-18 |
Study Overview
Brief Summary
This is a multi-center, phase II study to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory DLBCL.
Official Title
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Conditions
Diffuse Large B-cell Lymphoma (DLBCL)
Intervention / Treatment
- Biological: Tisagenlecleucel
- Drug: Lymphodepleting chemotherapy
Other Study ID Numbers
- CCTL019C2201
- 2014-003060-20
- 2014
Start Date (Actual)
2015-07-29
Primary Completion Date (Actual)
2022-12-22
Study Completion Date (Actual)
2022-12-22
Enrollment (Actual)
115
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Novartis Pharmaceuticals |
| Information Provided By: | Novartis |
| Last Update Posted: | 2024-04-18 |
Study Overview
Brief Summary
This is a multi-center, phase II study to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory DLBCL.
Official Title
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Conditions
Diffuse Large B-cell Lymphoma (DLBCL)
Intervention / Treatment
- Biological: Tisagenlecleucel
- Drug: Lymphodepleting chemotherapy
Other Study ID Numbers
- CCTL019C2201
- 2014-003060-20
- 2014
Start Date (Actual)
2015-07-29
Primary Completion Date (Actual)
2022-12-22
Study Completion Date (Actual)
2022-12-22
Enrollment (Actual)
115
Study Type
Interventional
Phase
Phase 2